Although the biomarkers assessed (albumin, CRP, BuChE, PON1, and haptoglobin) exhibit relatively low intra-individual variability, a single measurement does not fully capture the dynamic nature of inflammatory, oxidative, and metabolic processes that evolve throughout ALS disease progression. This evidence concerns the gene HP and amyotrophic lateral sclerosis.